Peritoneal dialysis, membranes and beyond

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue 6, 2006, Pages 571-576

  Margetts, Peter J ^a,b   Brimble, Kenneth S ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

^b T3309 ^*  (Canada)

Author keywords

Advanced glycation end products; Biocompatible; Nitric oxide; Peritoneal membrane; Solute transport; Ultrafiltration

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; BIOMATERIAL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICODEXTRIN; NITRIC OXIDE; PYRIDOXAL 5 PHOSPHATE; PYRIDOXAMINE; VERAPAMIL;

CLINICAL TRIAL; DNA POLYMORPHISM; EPITHELIUM; HUMAN; INFLAMMATION; META ANALYSIS; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PERITONEUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL REPLACEMENT THERAPY; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULTRAFILTRATION; WATER TRANSPORT;

ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; MEMBRANES; PERITONEAL DIALYSIS; PERITONEUM;

EID: 33750213979     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000247500.41420.94     Document Type: Review

References (59)

1. Rippe B, Rosengren BI, Venturoli D. The peritoneal microcirculation in peritoneal dialysis. Microcirculation 2001; 8:303-320.
2. Venturoli D, Rippe B. Transport asymmetry in peritoneal dialysis: application of a serial heteroporous peritoneal membrane model. Am J Physiol Renal Physiol 2001; 280:F599-F606.
3. Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol 2005; 288:F433-F442.
4. Krediet RT, Van Esch S, Smit W, et al. Peritoneal membrane failure in peritoneal dialysis patients. Blood Purif 2002; 20:489-493.
5. Keshaviah P, Emerson PF, Vonesh EF, Brandes JC. Relationship between body size, fill volume, and mass transfer area coefficient in peritoneal dialysis. J Am Soc Nephrol 1994; 4:1820-1826.
6. Rosengren BI, Rippe B. Blood flow limitation in vivo of small solute transfer during peritoneal dialysis in rats. J Am Soc Nephrol 2003; 14:1599-1604.
7. Nieuwdorp M, Mooij HL, Kroon J, et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 2006; 55:1127-1132. That the small vascular pores are complex structures, and the endothelial glycocalyx lining is influenced by a variety of factors, has been known for some time. The effects of changes in the pore-matrix on peritoneal solute transport have not been explored.
8. Davies SJ. Getting to grips with individual variation in membrane function. Perit Dial Int 2005; 25:35-37.
9. Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure. Peritoneal Dialysis International 2000; 20 (Suppl 4):S22-S42.
10. Ni J, Verbavatz JM, Rippe A, et al. Aquaporin-1 plays an essential role in water permeability and ultrafiltration during peritoneal dialysis. Kidney Int 2006; 69:1518-1525. This paper not only confirms the importance of aquaporin-1 in peritoneal water transport, but expands the use of transgenic animals to peritoneal dialysis research which increases our ability to define mechanisms of peritoneal membrane dysfunction.
11. Smit W, Struijk DG, Ho-dac-Pannekeet MM, Krediet RT. Quantification of free water transport in peritoneal dialysis. Kidney Int 2004; 66:849-854.
12. Heimburger O, Waniewski J. Ultrafiltration failure in peritoneal dialysis patients. Perit Dial Int 2004; 24:506-508.
13. Goffin E, Combet S, Jamar F, et al. Expression of aquaporin-1 in a long-term peritoneal dialysis patient with impaired transcellular water transport. Am J Kidney Dis 1999; 33:383-388.
14. Asghar RB, Diskin AM, Spanel P, et al. Influence of convection on the diffusive transport and sieving of water and small solutes across the peritoneal membrane. J Am Soc Nephrol 2005; 16:437-443.
15. Williams JD, Craig KJ, Topley N, et al., Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-479.
16. Sherif AM, Nakayama M, Maruyama Y, et al. Quantitative assessment of the peritoneal vessel density and vasculopathy in CAPD patients. Nephrol Dial Transplant 2006; 21:1675-1681.
17. Churchill DN, Thorpe KE, Nolph KD, et al. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1998; 9:1285-1292.
18. Rumpsfeld M, McDonald SP, Johnson DW. Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. J Am Soc Nephrol 2006; 17:271-278. This was a large observational study that confirmed many previous studies that have demonstrated the association between peritoneal membrane function and clinical outcomes.
19. Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:1307-1320.
20. Ates K, Nergizoglu G, Keven K, et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001; 60:767-776.
21. Brown EA, Davies SJ, Rutherford P, et al. Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol 2003; 14:2948-2957.
22. Jager KJ, Merkus MP, Dekker FW, et al. Mortality and technique failure in patients starting chronic peritoneal dialysis: results of The Netherlands Cooperative Study on the Adequacy of Dialysis NECOSAD Study Group. Kidney Int 1999; 55:1476-1485.
23. Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004; 66:2437-2445.
24. La Milia V, Pozzoni P, Virga G, et al. Peritoneal transport assessment by peritoneal equilibration test with 3.86% glucose: a long-term prospective evaluation. Kidney Int 2006; 69:927-933. This study, along with the Stoke-on-Trent longitudinal study by Davies [23], generated hypotheses about the association between peritoneal structure and function.
25. Devuyst O, Topley N, Williams JD. Morphological and functional changes in the dialysed peritoneal cavity: impact of more biocompatible solutions. Nephrol Dial Transplant 2002; 17 (Suppl 3):12-15.
26. Witowski J, Korybalska K, Wisniewska J, et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11:729-739.
27. De Vriese AS. The John F Maher Recipient Lecture 2004: Rage in the peritoneum. Perit Dial Int 2005; 25:8-11.
28. De Vriese AS, Flyvbjerg A, Mortier S, et al. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 2003; 14:2109-2118.
29. De Vriese AS, Tilton RG, Mortier S, Lameire NH. Myofibroblast transdifferentiation of mesothelial cells is mediated by rage and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant 2006; Jun 6 [Epub ahead of print]. This study further established the importance of AGE-RAGE interactions in peritoneal damage and specifically implicated a role of RAGE in epithelial mesenchymal transition.
30. Schwenger V, Morath C, Salava A, et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17:199-207. This study yielded important observations concerning the role of the AGE receptor in peritoneal inflammation, fibrosis, and angiogenesis using the transgenic mice deficient in RAGE. AGE-RAGE interaction has gained increased recognition as a factor in peritoneal injury and may lead to specific therapeutic intervention.
31. Pecoits-Filho R, Carvalho MJ, Stenvinkel P, et al. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 2006; 26:53-63.
32. Gillerot G, Goffin E, Michel C, et al. Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int 2005; 67:2477-2487. There is a wide variation in peritoneal membrane function at the initiation of dialysis and changes over time on dialysis. It is clear that there are environmental and patient-specific factors responsible for this. This study, along with two smaller previous studies, clearly demonstrated the role of gene polymorphisms in explaining this interpatient variability.
33. Wong TY, Szeto CC, Szeto CY, et al. Association of ENOS polymorphism with basal peritoneal membrane function in uremic patients. Am J Kidney Dis 2003; 42:781-786.
34. Combet S, Van Landschoot M, Moulin P, et al. Regulation of aquaporin-1 and nitric oxide synthase isoforms in a rat model of acute peritonitis. J Am Soc Nephrol 1999; 10:2185-2196.
35. Combet S, Ferrier ML, Van Landschoot M, et al. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 2001; 12:2146-2157.
36. Ni J, Moulin P, Gianello P, et al. Mice that lack endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis. J Am Soc Nephrol 2003; 14:3205-3216.
37. Ni J, Cnops Y, McLoughlin RM, et al. Inhibition of nitric oxide synthase reverses permeability changes in a mouse model of acute peritonitis. Perit Dial Int 2005; 25 (Suppl 3):S11-S14.
38. Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts I Paracrine cells important in health and disease. Am J Physiol Cell Physiol 1999; 277:C1-C9.
39. Margetts PJ, Kolb M, Galt T, et al. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001; 12:2029-2039.
40. Yanez-Mo M, Lara-Pezzi E, Selgas R, et al. Peritoneal dialysis and epithelial-tomesenchymal transition of mesothelial cells. N Engl J Med 2003; 348:403-413.
41. Margetts PJ, Bonniaud P, Liu L, et al. Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005; 16:425-436.
42. Aroeira LS, Aguilera A, Selgas R, et al. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis 2005; 46:938-948. Epithelial mesenchymal transition is a ubiquitous physiologic process and has gained increasing attention because of the central role of cellular transition in fibrosis and metastatic transformation in malignancy. This paper describes a follow-up study from an early paper by the same group that clearly identified epithelial mesenchymal transition in peritoneal dialysis patients. In this study, they have associated epithelial mesenchymal transition with angiogenesis through the production of vascular growth factors by transdifferentiated cells.
43. Tauer A, Knerr T, Niwa T, et al. In vitro formation of N(epsilon)-(carboxymethyl) lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 2001; 280:1408-1414.
44. Mortier S, Faict D, Lameire NH, De Vriese AS. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int 2005; 67:1559-1565. Although this is a rat model, it provides hopeful evidence that peritoneal membrane damage can be reversed by changing to biocompatible fluids. Human clinical data will be more difficult to obtain.
45. Mortier S, Faict D, Schalkwijk CG, et al. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. Kidney Int 2004; 66:1257-1265.
46. Williams JD, Topley N, Craig KJ, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66:408-418.
47. Kuriyama S, Otsuka Y, Iida R, et al. Reduction of peritoneal membrane permeability by long-term use of neutral-pH peritoneal dialysis solution: a preliminary report in high transporters. Clin Exp Nephrol 2004; 8:392-393.
48. Nishina M, Endoh M, Suzuki D, et al. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Clin Exp Nephrol 2004; 8:339-343.
49. Lee HY, Park HC, Seo BJ, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25:248-255. Unfortunately, this retrospective study was not randomized so did not provide confirmatory evidence of the benefits of biocompatible fluids. If these results can be replicated in a randomized, controlled trial, then the benefits of these new solutions may go beyond preservation of the peritoneal membrane.
50. Wiggins KJ, Rumpsfeld M, Blizzard S, Johnson DW. Predictors of a favourable response to icodextrin in peritoneal dialysis patients with ultrafiltration failure. Nephrology (Carlton) 2005; 10:33-36.
51. Davies SJ, Woodrow G, Donovan K, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14:2338-2344.
52. le Poole CY, van Ittersum FJ, Weijmer MC, et al. Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study. Adv Perit Dial 2004; 20:170-176.
53. Zareie M, Tangelder GJ, ter Wee PM, et al. Beneficial effects of aminoguanidine on peritoneal microcirculation and tissue remodelling in a rat model of PD. Nephrol Dial Transplant 2005; 20:2783-2792.
54. Kakuta T, Tanaka R, Satoh Y, et al. Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats. Kidney Int 2005; 68:1326-1336.
55. Nakamura S, Niwa T. Pyridoxal phosphate and hepatocyte growth factor prevent dialysate-induced peritoneal damage. J Am Soc Nephrol 2005; 16:144-150. AGEs seem to accumulate in many disease states including diabetes, uremia, and peritoneal dialysis. There is ample evidence to suggest AGEs have adverse physiological effects. This study in rats uses a novel agent that may decrease AGE formation without the toxicity associated with aminoguanidine.
56. Margetts PJ, Churchill DN. Acquired ultrafiltration dysfunction in peritoneal dialysis patients. J Am Soc Nephrol 2002; 13:2787-2794.
57. Kyuden Y, Ito T, Masaki T, et al. Tgf-beta1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int 2005; 25:483-491.
58. Duman S, Sen S, Duman C, Oreopoulos DG. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int J Artif Organs 2005; 28:156-163.
59. Rojas-Campos E, Cortes-Sanabria L, Martinez-Ramirez HR, et al. Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 2005; 25:576-582.